You are here:

ticagrelor (Brilique)

Advice

following a full submission:

ticagrelor 60mg film-coated tablets (Brilique®) is not recommended for use within NHS Scotland.

Indication under review: co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.

A large, phase 3, randomised, double-blind study in a high risk population who had suffered a myocardial infarction in the previous one to three years demonstrated that the addition of ticagrelor to aspirin significantly reduced the risk of ischaemic events (a composite of cardiovascular death, myocardial infarction and stroke).

The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: ticagrelor (Brilique)
SMC Drug ID: 1224/17
Manufacturer: AstraZeneca UK Ltd
Indication: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.
BNF Category:
Sub Category: 2.9 Antiplatelet drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 April 2017

Back